Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Willem J Remme

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Cardiology Clinics|December 8, 2007
Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?Willem J Remme
Cardiovascular Drugs and Therapy|October 11, 2002
PERindopril-Function of the Endothelium in Coronary Artery Disease Trial: the PERFECT study--sub study of EUROPA: rationale and designMichiel L Bots, Willem J Remme, Tomas F Lüscher, et al.
International Journal of Cardiology|February 3, 2007
Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular functionMichel E Bertrand, Willem J Remme, Kim M Fox, et al.
Archives of Cardiovascular Diseases|March 24, 2009
Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trialMichel E Bertrand, Kim M Fox, Willem J Remme, et al.
American Heart Journal|December 19, 2015
Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysisMichel E Bertrand, Roberto Ferrari, Willem J Remme, et al.
Cardiovascular Drugs and Therapy|March 1, 2008
Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failureJens Rosenberg, Finn Gustafsson, Willem J Remme, et al.
Cardiovascular Drugs and Therapy|February 23, 2011
Clinical Trials Update AHA Congress 2010John D Horowitz, Robert S Rosenson, John J V McMurray, et al.
Cardiovascular Drugs and Therapy|June 28, 2002
Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failureHenry A Glick, Sean M Orzol, Joseph F Tooley, et al.
Cardiovascular Drugs and Therapy|October 22, 2008
Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?Willem J Remme, Jaap W Deckers, Kim M Fox, et al.
American Heart Journal|March 27, 2007
Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery diseaseKim M Fox, Michel E Bertrand, Willem J Remme, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Cardiology Clinics|December 8, 2007
Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?Willem J Remme
Cardiovascular Drugs and Therapy|October 11, 2002
PERindopril-Function of the Endothelium in Coronary Artery Disease Trial: the PERFECT study--sub study of EUROPA: rationale and designMichiel L Bots, Willem J Remme, Tomas F Lüscher, et al.
International Journal of Cardiology|February 3, 2007
Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular functionMichel E Bertrand, Willem J Remme, Kim M Fox, et al.
Archives of Cardiovascular Diseases|March 24, 2009
Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trialMichel E Bertrand, Kim M Fox, Willem J Remme, et al.
American Heart Journal|December 19, 2015
Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysisMichel E Bertrand, Roberto Ferrari, Willem J Remme, et al.
Cardiovascular Drugs and Therapy|March 1, 2008
Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failureJens Rosenberg, Finn Gustafsson, Willem J Remme, et al.
Cardiovascular Drugs and Therapy|February 23, 2011
Clinical Trials Update AHA Congress 2010John D Horowitz, Robert S Rosenson, John J V McMurray, et al.
Cardiovascular Drugs and Therapy|June 28, 2002
Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failureHenry A Glick, Sean M Orzol, Joseph F Tooley, et al.
Cardiovascular Drugs and Therapy|October 22, 2008
Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?Willem J Remme, Jaap W Deckers, Kim M Fox, et al.
American Heart Journal|March 27, 2007
Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery diseaseKim M Fox, Michel E Bertrand, Willem J Remme, et al.
Pageof 4